SCHEMBL10088944

SCHEMBL10088944

O=CC1=Cc2ccc(-c3ccccc3C(F)(F)F)cc2OC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.39
TRPA1 O75762 3/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
BACE1 P56817 1/20 0.36
SCN9A Q15858 1/20 0.36
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
FFAR1 O14842 1/20 0.35
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 3/20 0.34
TSHR P16473 3/20 0.34
CYP2C19 P33261 3/20 0.34
CLK4 Q9HAZ1 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPK1 P28482 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10088925 0.80 CA9 (0.48) PTGS1PTGS2ALDH1A1
SCHEMBL10088926 0.79 CA9 (0.43) PTGS1PTGS2
SCHEMBL10088907 0.79 ALOX5 (0.40) PTGS1PTGS2
SCHEMBL10088509 0.77 FFAR1 (0.39) PTGS1PTGS2FFAR1
SCHEMBL10088526 0.75 MAOB (0.44) ARLMNA
SCHEMBL10088928 0.75 PDE3B (0.38) PTGS1PTGS2ALDH1A1LMNAHIF1A
SCHEMBL10088997 0.74 MAOB (0.41) ARFFAR1CYP1A2CYP2C19ALDH1A1
SCHEMBL2327634 0.73 MAOA (0.32) TRPA1FFAR1LMNA
SCHEMBL10088938 0.72 CA12 (0.35) PTGS1PTGS2ALDH1A1
SCHEMBL10088988 0.72 S1PR5 (0.44) LTB4RLTB4R2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 AR 559/4885TRPA1 272/4885TRPM8 191/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 AR 398/4885TRPA1 297/4885TRPM8 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.